Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DICLOTAM study of diclofenac-tamoxifen pharmacokinetic interaction in breast cancer
NL-OMON48096Phase 4Withdrawn
- Sponsor
- Erasmus MC
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of diclofenac and tamoxifen in breast cancer, sponsored by Erasmus MC. Primary endpoint: Endoxifen AUC. Planned start Jan 2019; status: withdrawn.
02
Drugs
diclofenactamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON48096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48096.